Global hemoglobinopathies market is segmented on the basis therapeutics and geography. The therapeutic segment includes various drugs such as NiCord, ZFP Transcription Factors, ALN-TMP, Drug Targeting PRMT5 and Drug Targeting Protein Arginine Methyltransferase 5. ALN-TMP is a subcutaneous RNAi therapeutic that targets Tmprss6 and is used in the treatment of ß-thalassemia. NiCord®, based on the novel NAM technology, is a potential solution for a number of diseases such as thalassemia, sickle cell disease, hematological malignancies, severe rare genetic metabolic diseases and autoimmune diseases. Geographically, the global hemoglobinopathies market is segmented into North America, Europe, Asia-Pacific and LAMEA. Africa is the leading market for these drugs due to the high prevalence of hemoglobinopathies in the region.
The report provides an overview of the global hemoglobinopathies market, which includes drivers, restraints and opportunities to help professionals better understand market behavior
Detailed information regarding R&D activities, pipeline research, partnerships, licensing and collaborations in the global hemoglobinopathies market would be informative for professionals in the corporate sector
Pin-point analysis of geographic segments would help stakeholders identify opportunities for growth within the global hemoglobinopathies market
Porter’s Five Forces analysis examines the competitive structure of the global hemoglobinopathies market and would assist market strategists in their decision making process
KEY MARKET SEGMENTS
The global hemoglobinopathies market is segmented into two major categories: pipeline therapeutics and geography.
MARKET BY PIPELINE THERAPEUTICS
ZFP Transcription Factors
Drug Targeting PRMT5
Drug Targeting Protein Arginine Methyltransferase 5
MARKET BY GEOGRAPHY
* This report will be delivered in 12 Business Days. *